Among 307,025 UK Biobank participants, carriers of clonal hematopoiesis of indeterminate potential (CHIP) mutations showed 14% higher odds of advanced cardiovascular-kidney-metabolic syndrome stages and 13% increased cardiovascular disease risk during follow-up. Most striking, CHIP carriers at the highest metabolic risk stage faced 63% greater cardiovascular hazard compared to non-carriers. This preprint identifies CHIP as a previously overlooked inflammatory driver that compounds metabolic dysfunction's cardiovascular toll. The finding represents a significant advance in personalized cardiovascular prevention, as CHIP testing could identify high-risk individuals who appear similar by conventional metabolic markers. Unlike traditional risk factors that plateau with age, CHIP mutations accumulate throughout life and drive chronic inflammation independently of lifestyle factors. The research suggests blood-based genetic screening could revolutionize cardiovascular risk assessment, particularly for metabolically compromised patients. However, this preprint awaits peer review, and the practical implementation of CHIP testing remains costly and technically complex. The study's observational design also cannot establish whether CHIP directly causes accelerated cardiovascular disease or merely marks individuals with heightened inflammatory susceptibility. Nevertheless, integrating CHIP into clinical algorithms could transform how physicians stratify and treat cardiovascular risk.